AI assistant
Vaxcyte, Inc. — Director's Dealing 2024
Sep 5, 2024
31100_dirs_2024-09-05_f6ab8c3f-e248-4530-98d2-cfaee28ecf89.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Vaxcyte, Inc. (PCVX)
CIK: 0001649094
Period of Report: 2024-09-03
Reporting Person: Cowan Elvia (SVP, FINANCE)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-09-03 | Common Stock | M | 5000 | $25.92 | Acquired | 17723 | Direct |
| 2024-09-03 | Common Stock | S | 5000 | $107.67 | Disposed | 12723 | Direct |
| 2024-09-03 | Common Stock | F | 1145 | $110.15 | Disposed | 11578 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-09-03 | Stock Option (right to buy) | $25.92 | M | 5000 | Disposed | 2032-08-08 | Common Stock (5000) | Direct |
Footnotes
F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2023.
F2: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of restricted stock units. No other shares of common stock subject to the restrictions on transfer set forth in a Lock-Up Agreement dated September 4, 2024 were sold by the Reporting Person.
F3: 1/4 of the shares subject to the option vested on July 1, 2023, and 1/48 of the shares shall vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.